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David R. Holmes, JR, MDP rofessional society guidelines are founded onrandomized clinical trials (RCTs), thought tobe the highest level of science. However,
medical practice is not only science-based, but an
art, requiring data integration into a wisdom matrix,
which is then focused and individualized for the
speciﬁc patient. In this latter regard, scientiﬁc study
is crucial, but has well-known limitations, high-
lighted by considerations related to RCTs. These
limitations include (among others) typical trial
enrollments of a small, very carefully selected subset
of the total group of patients with the disease/
therapy being studied; constrained, highly focused
endpoints; and rigid protocols. Furthermore, back-
ground treatment strategies may change over the
course of the study, which can affect its power to
reach unequivocal conclusions. Finally, the target
endpoint’s incidence may be so low that a composite
endpoint is used, leaving the most important single
endpoint unresolved. Such issues make it difﬁcult
to translate science into the art of caring for a spe-
ciﬁc patient, who may not ﬁt exactly into the RCT
framework.
The SECURITY (Second Generation Drug-Eluting
Stent Implantation Followed by Six- Versus Twelve-
Month Dual Antiplatelet Therapy) trial (1), which
studied the impact of 6 months versus 12 months of
dual antiplatelet therapy (DAPT) in patients treated
with 1 of several second-generation drug-eluting
coronary stents (DES), exempliﬁes the conundrum
resulting from this situation. This question is of great
clinical interest, initially focused on the occurrence
of stent thrombosis, a highly morbid, even mortal
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entiﬁc study efforts. The development of speciﬁc,
widely accepted deﬁnitions (3,4) greatly improved
the situation. This problem was the subject of mul-
tiple single registry and multiregistry experiences, as
well as smaller RCTs, resulting in varying guidelines
and practice patterns around the world (5–13). The
etiology has been accorded great attention. Initially,
crucial small observations focused on the central role
of platelets as the most important putative mecha-
nism. Accordingly, a variety of antiplatelet strategies
were put into place, of which DAPT is dominant.
Such a strategy carries multiple issues including:
1) bleeding, for which the risk increases the longer a
patient is on these agents; 2) its cost and side effects;
and 3) the clinical need to consider drug discontinu-
ation should subsequent surgery be required. Each of
these issues has great patient care implications.
Given that stent thrombosis timing ranges from early
to very late (up to several years after implantation),
DAPT duration is of substantial interest. Early on,
different regimens were recommended without a
substantial scientiﬁc basis, generally on the basis of
expert consensus. For example, the American College
of Cardiology/American Heart Association guidelines
currently recommend 12 months of DAPT in patients
treated with DES “if the patient is not at high risk of
bleeding” (5).
By contrast, the European Society of Cardiology
guidelines state, “routine extension of DAPT beyond
6 months after new-generation DES implantation in
stable coronary artery disease cannot be recom-
mended and observational data.suggest that even
shorter durations of DAPT may be sufﬁcient.” (6).
Even longer DAPT duration is currently being tested
in the largest RCT, to be presented in the fall of 2014
(12). Both professional guidelines were initially
developed for ﬁrst-generation DES (which may
have a different proﬁle and higher frequency of
stent thrombosis) and were often on the basis of
expert consensus and smaller RCTs that were often
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2099underpowered to provide deﬁnitive conclusions.
Ideally, a study such as the SECURITY trial
might answer the question of DAPT duration. The
SECURITY trial included 1,399 patients in a pro-
spective, randomized, noninferiority multicenter
international trial, who were treated with 1 of
several second-generation DES types. The patient
groups were well matched: 31% had diabetes; 20.7%
had a prior myocardial infarction; 43.8% had more
than single-vessel disease; and 38.4% had unstable
angina. Conventional treatment with clopidogrel
75 mg/day for at least 3 days before the procedure,
or a loading dose of at least 300 mg in patients not
on chronic clopidogrel was used. Although newer
antiplatelet agents were allowed by protocol
amendment after their approval, >95% of patients
were treated with clopidogrel. Post-procedure, ace-
tylsalicylic acid (aspirin) was prescribed indeﬁnitely.
Randomization focused on administering 75 mg of
clopidogrel for either 6 or 12 months. At the 12-
month primary endpoint follow-up, DAPT was still
used clinically in 33.8% of the 6-month group (thus
muddying the water) and was continued in 96.1%
of the 12-month group. The primary endpoint
was the composite of cardiac death, myocardial
infarction, stroke, Bleeding Academic Research
Consortium (BARC) type 3 or 5 bleeding, and (very
importantly) deﬁnite or probable stent thrombosis at
12 months. A noninferiority design was used with an
absolute margin of 2.0% in the difference of event
proportions. Using this margin, a power of 0.80, and
a 1-tailed 0.05 signiﬁcance level, an estimated 1,370
patients were needed per group. Very low complica-
tion rates in both treatment arms led to early termi-
nation of the trial as a result of “enrollment futility
because of minimal differences in the rate of the
primary endpoint between the 2 groups.” (1). There
were no signiﬁcant differences in the primary com-
posite endpoint or in any individual components. In
particular, there were no signiﬁcant differences in
either deﬁnite or probable stent thrombosis at
either 12 months (0.3%) or 24 months (0.4%), which
occurred very infrequently. Notably, despite the
longer DAPT duration, type 3 or 5 BARC bleeding was
not signiﬁcantly increased in the 12-month therapy
group, although event numbers and rates were very
small (4 [0.6 %] vs. 8 [1.1%]; p ¼ 0.283).
The investigators provide an excellent discussion
of previously published studies with different trials
and trial designs, illustrating the ﬁeld’s complexity,
with some studies focusing on target vessel failure,
others on varying composites, and substantial vari-
ability in DAPT duration. With respect to the latter,
some prior studies evaluated 3 versus 12 months,others evaluated 6 versus 24 months. Confounding
variables included patient demographics (either
acute coronary syndromes or more stable patients),
and noninferiority boundaries for statistical assess-
ment. In this issue of the Journal, Colombo et al. (1)
conclude with their trial’s limitations, which have
much in common with previous studies. These
include: that their trial is underpowered; results
cannot be generalized to higher-risk patients and
lesions; approximately one-third of the 6-month
control group continued with DAPT, and the pri-
mary endpoint was lower than expected; there were
several different second-generation DES used; and
there was a wide margin of noninferiority used for
analysis. Using multivariable adjustment, they found
that DAPT duration does not independently predict
the primary endpoint, but stenting procedure–related
factors (e.g., mean stent length, size, and number)
were strong, independent primary endpoint pre-
dictors, as were some baseline characteristics, such as
age. No conclusions could be made regarding speciﬁc
stent type because of the small sample sizes. Such
limitations have very real clinical implications for
day-to-day practice.The scientiﬁc underpinnings of the crucial debate
on the duration of DAPT required to optimize the
safety and efﬁcacy of current, more advanced-
generation DES remain somewhat wobbly; different
societal guideline documents reviewing the same data
reached somewhat different conclusions. In this case,
art and some attempt at wisdom are needed to help
decide what to recommend for Mr. or Mrs. Smith,
whom you have just treated with 1 of several second-
generation DES. That process must include informa-
tion about exactly who they are, what their lesions
were like, details of the speciﬁc stent approach (e.g.,
number and size of stents, adequacy of the result), how
the procedure went, their risk for bleeding, the po-
tential need for subsequent surgical procedures, their
tolerance of unknowns, and often other mitigating,
unmeasurable data. In considering these issues, art
plays a prominent role. With patients similar to those
in the SECURITY trial, and in the absence of rigorous
data to the contrary, shorter DAPT duration seems very
reasonable to consider and is increasingly used in the
art of taking care of these patients.
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